Arceli Lifescience Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 06-07-2024
- Paid Up Capital ₹ 2.27 M
as on 06-07-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 Cr
as on 06-07-2024
- Revenue %
(FY 2023)
- Profit -239.07%
(FY 2023)
- Ebitda -121.95%
(FY 2023)
- Net Worth 47.08%
(FY 2023)
- Total Assets 110.13%
(FY 2023)
About Arceli Lifescience
The Corporate was formerly known as Arceli Agribiz Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.27 M.
The company currently has active open charges totaling ₹1.50 Cr.
Aditya Shah and Palak Shah serve as directors at the Company.
- CIN/LLPIN
U01110MH2019PTC324275
- Company No.
324275
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Apr 2019
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Arceli Lifescience Private Limited offer?
Arceli Lifescience Private Limited offers a wide range of products and services, including Essential & Aromatic Oils, Spice Oil, Essential Oils, Carrier Oil, Ayurvedic & Herbal Extracts, Plant Extracts, Seeds Oil and Fruit Oils, Herb Oil.
Who are the key members and board of directors at Arceli Lifescience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Shah  | Additional Director | 27-Apr-2021 | Current |
| Palak Shah | Director | 19-Apr-2019 | Current |
Financial Performance of Arceli Lifescience.
Arceli Lifescience Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 239.07% decrease in profit. The company's net worth Soared by an impressive increase of 47.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arceli Lifescience?
In 2023, Arceli Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Baroda Goods Transport Service Private LimitedActive 37 years 8 months
Aditya Shah is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 16 Sep 2022 | ₹1.50 Cr | Open |
How Many Employees Work at Arceli Lifescience?
Unlock and access historical data on people associated with Arceli Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arceli Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arceli Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
